In-Depth Value Research on IDEXX Laboratories

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow large is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?6/10

  A

  Conclusion: the ceiling is large enough to support a great company, but IDEXX is mainly deepening and enlarging an existing pie by raising penetration in pet diagnostics, rather than creating a new market from nothing. Measured against Baillie Gifford LTGG's yardstick of 5x in 10 years, the ceiling is high enough, as the industry is still expanding and diagnostic penetration is far from saturated. But its shape is an installed-base upgrade story, not a greenfield frontier story, which means the growth curve looks more like a steady climb than an exponential breakout.

  Start with the size of the broader market. The report cites total 2025 U.S. pet industry spending of about $158 billion, with APPA expecting about $165 billion in 2026 and roughly 95 million pet-owning households in the United States. But IDEXX's real market is the veterinary diagnostics segment, not total pet spending. Its 2025 total revenue was $4.304 billion. Against an industry spending pool measured in the hundreds of billions, there is clearly still substantial penetration room. But the diagnostics pie itself is not that large. Its growth comes from the combination of more tests per visit, meaning higher diagnostic intensity, instrument placement expansion, and pricing, rather than opening up demand that did not previously exist.

  That is the essence of enlarging an existing pie: pets visiting veterinarians and having bloodwork done is a clinical setting that has existed for decades. What IDEXX does is turn tests that were previously sent to outside laboratories, or simply not performed, into results delivered within minutes on an in-clinic Catalyst/inVue analyzer, thereby raising testing penetration per visit. In the report, CAG, the companion animal group, generated 2025 revenue of $3.953 billion, about 91.9% of total revenue, while CAG Diagnostics recurring revenue alone was $3.407 billion, about 79.2% of total revenue. This main growth line comes from existing clinics doing more testing, not from entering a brand-new industry.

  Is there any element of market creation? Some, but its weight is limited. IDEXX Cancer Dx and inVue Dx, as discussed in the report, bring oncology/cytology diagnostics that previously relied on send-out laboratories and manual microscopic review into the clinic, with AI-assisted real-time results. IDEXX estimates this unlocks an approximately $1.1 billion canine cancer diagnostics addressable market. This is closer to carving out a valuable new menu inside the existing diagnostics pie, for tests that were previously hard to do. It is real incremental growth, but relative to the company's $4.3 billion scale, it is an enhancement rather than a second IDEXX.

  Judged honestly through the Baillie Gifford lens, the height of the ceiling is adequate: a long runway, low penetration, and strong repeat usage are the foundation for long-term ownership. But the nature of the ceiling is installed-base upgrading rather than disruptive frontier expansion, which makes it difficult to replicate the blue-sky elasticity of a market moving from zero to one and revenue jumping 10x. The full-year guidance in the report also confirms this steady rather than explosive rhythm: 2026 revenue guidance was raised to $4.675 billion to $4.760 billion, implying high-single-digit organic growth. This is steady expansion by a top student, not the exponential lift-off of a new market.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth mainly driven by volume, price, or new businesses?4/10

  A

  Conclusion: revenue at least doubling over the next five years is almost impossible. This is IDEXX's weakest fit within the Baillie Gifford question set. The company is already large, and its growth rate is a steady high single digit. Doubling in five years requires a compound growth rate of about 15% per year, while IDEXX's realistic growth center is only about 8%-11%, implying roughly +50% over five years, nowhere near the doubling threshold. Structurally, growth is a mix of price first, volume second, and new businesses as an embellishment. It lacks an explosive engine that could lift the curve to a doubling slope.

  Start with the hurdle. Doubling revenue in five years means a compound annual rate of about 14.9%. Then compare that with IDEXX's actual pace: 2025 revenue was $4.304 billion, up about 10% year over year; 2026 first-quarter revenue was $1.141 billion, +14% as reported and +11% organically. But management set full-year guidance at $4.675 billion to $4.760 billion, implying reported growth of about 8.6%-10.6% and organic growth of about 7.7%-9.7%. In other words, even management's most optimistic full-year framing is only high single digit to low double digit. The first quarter's 14% includes currency and base effects, not a sustainable doubling slope. The report also places the base-case Owner Earnings growth rate in the 5%-8% annual range and explicitly does not mechanically extrapolate the one-year 2026 guidance increase over 10 years.

  What drives growth? Broken down, it is price >= volume > new businesses:

  • Price, meaning price increases/price realization. The report repeatedly notes contributions from higher realized prices / net price realization in the 2025 and first-quarter revenue increase, while first-quarter gross margin also improved by about 90 basis points year over year. In an inflationary environment, IDEXX has more pricing power than most testing/equipment suppliers. This is the most stable part of growth, but pricing contributes in the single digits and cannot support a doubling.
  • Volume, meaning placements plus diagnostic penetration. In the first quarter, the global premium instrument installed base grew 12% year over year, with about 1,100 new inVue Dx placements. Placement expansion brings later repeat revenue from consumables/laboratories, the razor-holder-and-razor-blade flywheel, but it is constrained by U.S. pet visit volumes. The report notes that the industry saw several guidance cuts in 2024 because visits slowed, so the volume leg cannot reliably deliver high growth.
  • New businesses, meaning Cancer Dx / inVue Dx / software and data. This is the most elastic but smallest piece in absolute terms. IDEXX Cancer Dx unlocks an approximately $1.1 billion canine cancer diagnostics addressable market. It is real incremental growth, but against a $4.3 billion base, it is unlikely to change the overall growth order of magnitude in the near term.

  Baillie Gifford would ask whether the blue-sky scenario can be higher. Honestly, even in IDEXX's upside case, the best outcome is high-single-digit organic growth plus pricing, installed-base penetration, and new menus adding up to roughly low-double-digit growth, implying about +60%-70% over five years and still falling short of a double. Its value is not in doubling in five years, but in more than 10 years of steady repeat usage, menu expansion, and buybacks that reduce share count, together lifting intrinsic value per share. This is a high-quality compounding machine, not a five-year doubling growth rocket. On this question, the honest answer is that it does not meet the bar.

  Jun 11, 2026
• QAfter five years, what will take over as the next growth engine? Does this second curve exist today?4/10

  A

  Conclusion: the second curve does exist today, but it is still an extension of the main curve rather than an independent new engine. It can extend growth, but it is unlikely to take over as the next pole of a much larger order of magnitude. IDEXX's next phase of growth mainly comes from three areas: in-clinic real-time oncology/cytology diagnostics, namely Cancer Dx plus inVue Dx; software and data platforms; and continued geographic and menu penetration. All three have landed and are contributing, but they essentially thicken and deepen the razor-blade menu. They do not leave the main channel of pet diagnostics, so this is a second acceleration lane rather than a second track.

  The area that most resembles a second curve is in-clinic AI diagnostics. inVue Dx moves cytology/oncology interpretation that previously relied on send-out laboratories and manual microscopic review into the clinic, with AI-assisted results in minutes. In the first quarter, the company added about 1,100 inVue Dx placements, while the global premium installed base rose +12% year over year. The accompanying IDEXX Cancer Dx turns cancer testing into a high-value new menu. IDEXX estimates it unlocks an approximately $1.1 billion canine cancer diagnostics addressable market, with mast cell tumor testing starting in North America in mid-2026 and rolling out internationally during the year. This is a second curve that exists today and is scaling, with real quality. But it remains vertical depth in pet diagnostics, not a new industry.

  The second area is software and data. The report notes that in 2024 the company acquired a U.S. private software and data platform business, expanding cloud-native workflows and providing customers with strategic data solutions. Software recurring revenue already reached $276 million. The point of software is not its revenue scale by itself, but that it binds diagnostic results, workflows, and customer data into a deeper network, reinforcing the switching costs of the diagnostics core business. It is a moat widener, but its scale as an independent growth pole is limited.

  The third area is geographic and menu penetration. The report notes that the company can use core reference laboratories to serve samples from other states and countries, expanding coverage without expanding the laboratory footprint in lockstep. This is leveraged extension of the installed platform and a steady source of growth, but it does not qualify as a new curve.

  Judged honestly from Baillie Gifford's perspective of concentrating firepower on years 3-10, IDEXX does not lack seeds for a second curve. What it lacks is a new engine, different in dimension from the core business, that can lift the overall growth rate to a new level. Its second curves, in-clinic AI oncology diagnostics and software/data, already exist, point in the right direction, and contribute marginal growth. That is much stronger than companies whose second curve is still stuck in a slide deck. But all these engines grow on the pet diagnostics tree. They are more likely to help the company maintain a high-single-digit-plus steady state than to create a new track with a step-change in revenue scale. So the answer is: the second curve is real and positive, but it extends the runway rather than shifting gears.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion: the core competitive advantage is systemic switching cost and economies of scale built by layering analyzers, consumable menus, reference laboratories, software, and service. It is not a single patent, but a full stack of compound stickiness embedded in clinics' daily workflows. Over the next three to five years, this moat is more likely to remain stable to slightly wider than to narrow materially. The forces widening it come from deeper software, data, and in-clinic AI diagnostics. I would not call it clearly widening because vertical integration by large hospital chains, competition from Antech/Zoetis, and the potential disruption of AI in interpretation are all real pressures.

  The core of the moat is switching cost. The report discloses that the company uses customer commitment arrangements to bind in-clinic instrument placements to future consumable/service revenue, with related contract assets totaling about $319 million as of the first quarter. The global premium installed base grew 12% year over year in the first quarter. Once a clinic has embedded IDEXX analyzers, consumables, reference laboratories, and software interfaces into daily operations, switching suppliers means changing workflows, training, data interfaces, and doctors' habits. That is the source of stickiness in this razor-holder-and-razor-blade business, and it explains why CAG Diagnostics recurring revenue can remain stable at $3.407 billion, about 79.2% of total revenue.

  The second pillar is economies of scale. IDEXX's 2025 CAG revenue was about $3.953 billion, while the closest listed peer, Zoetis, had only about $434 million in animal health diagnostics revenue, almost an order-of-magnitude gap. Larger sample volume means denser menus, stronger fixed-cost absorption, and faster laboratory turnaround. The report also notes that the company can use core laboratories to serve samples from other states/countries and expand coverage. This scale advantage translates directly into pricing power and margins: 2025 gross margin was 61.8%, with an operating margin of 31.6%. That is evidence of a moat converting into profit, not an empty claim.

  Whether the moat widens or narrows over the next three to five years requires looking at both sides. Forces that widen it: inVue Dx in-clinic AI cytology, the Cancer Dx oncology menu, and the software/data platform acquired in 2024 deepen the moat from hardware plus consumables into clinical decision-making plus software plus data, with software and data becoming stickier the more they are used. Pressures that narrow it: the report states directly that Antech, owned by Mars, has North America's largest veterinary reference laboratory network, while Zoetis is also investing in point-of-care and reference laboratories; consolidation among customers, including large groups such as Mars and NVA and buying consortiums, will raise bargaining power and may shift orders; AI/ML could also lower barriers in some interpretive work. The report's summary is restrained: the moat overall is stable to slightly wider, not clearly narrowing, and the company itself also acknowledges that patents cannot be treated as an absolute barrier.

  From a Baillie Gifford perspective, this moat is wide and being reinforced, good enough for an owner with a 10-plus-year horizon. The real risk is not that the moat collapses, but that its widening pace may slow under chain bargaining power and AI disruption. That would weaken the compounding slope needed for 5x in 10 years, but it is unlikely to materially narrow the moat within three to five years.

  Jun 11, 2026
• QIf the core business is disrupted, does it have the genes to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Conclusion: IDEXX has an evolutionary gene of continuous iteration and using new technology to disrupt itself, but what it has experienced is gradual self-renewal, not the life-or-death ordeal of reinventing itself after the core business is fully disrupted. That gene has not yet been tested in a true existential crisis. On mistakes and bad news, the company shows a practical, candid, non-defensive style: it proactively cuts guidance during industry headwinds, discloses risks thoroughly, and maintains governance discipline. That makes it qualified and somewhat strong on self-correction, but its extreme resilience after disruption can only be described as suggested, not disproven, and not yet proven.

  Start with the gene for self-reinvention. The strongest evidence is IDEXX's willingness to use point-of-care diagnostics to cannibalize its own send-out laboratory business. inVue Dx moves cytology/oncology interpretation that had been sent to reference laboratories and relied on manual microscopy into clinics, with AI-assisted results in minutes. In the first quarter it added about 1,100 inVue Dx units, while the global premium installed base rose +12% year over year. That means it is proactively shifting some high-margin reference laboratory samples into in-clinic point-of-care testing. This is an evolutionary act of disrupting itself, not clinging to old cash flows. Together with the Cancer Dx new menu and the 2024 acquisition of a software/data platform, the company has shown an ability to keep renewing itself inside the core business.

  But the distinction matters: this is active iteration, not forced rebirth. IDEXX has never faced a moment when an external force overturned its core business model as a whole. The closest stress tests in the report are economic/industry headwinds. In 2022, operations were pressured and operating cash flow fell to $543 million, but the company still generated about $899 million of operating profit, $679 million of net income, and about $394 million of free cash flow. When industry visit volumes slowed in 2024, the report says the company merely cut annual guidance several times rather than falling into a structural crisis. These prove strong stress resilience, but they are not tests at the level of core-business disruption. The true potential disruptions, such as AI fully commoditizing diagnostic interpretation or large chains building closed-loop diagnostics in-house, have not yet occurred. So the gene for last-ditch reinvention cannot currently be proven. One can only say the company's evolutionary tendency is a positive signal.

  Now consider how it handles mistakes and bad news. This is a clear positive. First, it admits and corrects: the report cites Reuters that in 2024 the company cut annual revenue expectations several times because of slowing visit volumes, and candidly attributed the issue to inflation and clinic staffing challenges, rather than glossing over it. Second, risk disclosure is thorough: the 10-K directly lays out hard risks such as customer chain bargaining power, single-source suppliers, including Catalyst chemistry slides' reliance on Ortho, and intensifying competition as AI advances, instead of dressing them up. Third, governance has complete correction mechanisms: according to the 2026 proxy cited by the report, the company has a clawback policy, no hedging or pledging, and PSUs tied to a 3-year performance period. These institutional arrangements mean mistakes have recovery mechanisms, rather than being allowed to run unchecked.

  Judged through the Baillie Gifford lens, Baillie Gifford favors companies that can reinvent themselves when the core is threatened and face bad news calmly. IDEXX meets and somewhat exceeds the bar on candid handling of bad news and continuous self-iteration. On the higher standard of rebirth after core disruption, it has the right evolutionary tendency but lacks true life-or-death validation. The conclusion: the self-correction gene is credible, while extreme reinvention resilience remains to be tested. This is a top student that keeps evolving, but it has not yet been pushed to the cliff edge where survival requires rebirth.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term mindset and deep alignment with the company? Is it willing to sacrifice current profit for the next five to ten years?4/10

  A

  Conclusion: management's long-term mindset and discipline are qualified and somewhat strong, but deep alignment with the company is weaker. This is not a founder-controlled owner-operator company. Alignment comes more from compensation design and professional reputation than from a large amount of personal capital. Is it willing to sacrifice current profit for five to ten years out? The answer is yes, with a track record, but the style is restrained investment by high-quality professional managers, not a founder's all-in bet.

  Start with the weak point in alignment, which must be stated honestly. The report discloses that all directors and current executives together hold only about 634,398 shares, or about 0.79% of outstanding shares, while former CEO Mazelsky held about 322,720 shares in total as of March 8, 2026. At the current share price of about $557, the June 10 close, with a market value of about $43.9 billion, total insider ownership is worth about $350 million. The absolute amount is not small, but it is tiny relative to the company's scale. This means management-shareholder alignment is mainly tied through compensation contracts, not through the founder-style binding of having one's net worth in the stock. Baillie Gifford particularly favors founders with deep ownership who are willing to burn near-term profit for the long term. On this dimension, IDEXX is institutionally aligned, not bloodline aligned.

  But compensation and governance discipline are genuinely solid, offsetting part of the alignment shortfall. The report cites the 2026 proxy: the CEO's share ownership target is 10x salary, executive vice presidents' target is 4x, and all NEOs met the requirement by the end of 2025; the company explicitly has no hedging, no pledging, no below-market option grants, no single-trigger change-of-control bonuses, no supplemental executive retirement plan, and a clawback policy; since 2024 it has introduced PSUs with a 3-year performance period to strengthen the link to long-term performance. Equity compensation is also restrained: 2025 share-based compensation expense was about $60.01 million, only about 1.4% of revenue. This is a framework of long-term orientation, compensation discipline, and shareholder alignment awareness. It is not perfect, but clearly above average.

  The succession arrangement confirms a long-term mindset. The CEO transition was executed smoothly in May 2026: Jay Mazelsky stepped down as CEO, became Executive Chair for 1 year before retirement, and was succeeded by Mike Erickson, who had 14 years of management and innovation experience at IDEXX. This was a well-prepared transition centered on an internal successor, not a celebrity external hire or reactive replacement. For long-term owners, that is more reassuring and shows the board has been planning around the people question years in advance.

  Is management willing to sacrifice current profit for five to ten years out? There is a positive record, but the spending is restrained. Evidence: the company has long paid no dividend, prioritizes cash for internal reinvestment and small acquisitions, including about $81.10 million for a software/data platform in 2024 and about $15.60 million for reference laboratory customer-relationship intangibles in 2025, and keeps investing in new menus such as inVue Dx and Cancer Dx. In the first quarter, even with higher R&D and commercialization spending and about $5 million of equity investment losses, it still maintained an operating margin of 31.8%. This shows it balances long-term investment and current margins. It is the steady approach of a top-quality company, not a founder's aggressive decision to crush profit for a market 10 years out.

  Overall, with the report scoring management and capital allocation at 4/5, management is trustworthy, long-term, disciplined, and has stable succession. The main deduction is low absolute insider ownership and the lack of founder-style deep alignment. Measured by the Baillie Gifford yardstick, this is a management team that cannot rely on sentiment but can rely on systems: dependable, but missing the rare tension of a founder willing to pay almost any near-term price for the long term.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?6/10

  A

  Conclusion: if IDEXX disappeared tomorrow, veterinarians and pet hospitals would miss it badly. Its in-clinic diagnostic analyzers, consumable menus, reference laboratories, and software workflows are already embedded in daily clinical practice, and there would be no substitute with the same depth in the short term. Its growth model is highly sustainable and basically does not depend on harming society or crossing regulatory red lines. It instead creates positive value by helping pets be diagnosed earlier and treated better. On this dual test of indispensability plus social/regulatory sustainability, IDEXX passes on both sides. This is the most solid aspect of the company as a long-term holding.

  Start with indispensability. The measure is how painful and hard to replace it would be if removed. IDEXX's products are not optional consumer upgrades; they are clinical decision-making tools for clinics: blood tests, real-time results, and oncology/cytology interpretation directly determine how doctors diagnose and prescribe. Its stickiness is visible in two hard numbers: CAG Diagnostics recurring revenue reached $3.407 billion, about 79.2% of total revenue, showing customers rely on it repeatedly and steadily; the global premium installed base was +12% year over year in the first quarter, and instruments, consumables, reference laboratories, and software interfaces have been tied into one workflow. Switching means changing processes, training, data interfaces, and doctors' habits. If IDEXX disappeared, clinics would not simply switch brands; a piece of the clinical workflow would be pulled out. That is high indispensability.

  Objectively, though, its indispensability is real at the industry level but not uniquely absolute. The report makes clear that Antech, owned by Mars, has North America's largest veterinary reference laboratory network, while Zoetis is also building out point-of-care and reference laboratory combinations. In other words, capable substitutes exist over the long term. It is just very hard to replace IDEXX in place, immediately, and with low friction over the short to medium term. Customers would miss it, but not to the point that the sky would fall with no alternative.

  Now consider the social and regulatory sustainability of its growth model. IDEXX has almost no dark side here. Its growth comes from three places, each of which stands up to scrutiny:

  • Pricing. The report notes net price realization contributions in 2025 and the first quarter, but this is pricing for real clinical value, not extracting rents from patients through monopoly power. Pet diagnostics does not involve pressure on human medical insurance, and it does not have a structure built on profiting by harming consumers.
  • Diagnostic penetration and placements. Encouraging more testing during more visits essentially means disease is found earlier and pets are treated earlier. This is a positive externality, not a gray zone of manufacturing excessive care. In veterinary settings, the social controversy around over-testing is far lower than in human healthcare.
  • New menus, Cancer Dx / inVue Dx. Bringing oncology/cytology diagnostics into the clinic and unlocking an approximately $1.1 billion canine cancer diagnostics addressable market directly serves earlier diagnosis of cancer in pets, a positive social value.

  The regulatory side is also clean. The risks disclosed in the report are single-source supply chain risk, including reliance on Ortho for Catalyst chemistry slides, customer chain bargaining power, and intensifying competition. These are operating risks, not a business model built on regulatory arbitrage or shifting social costs. The report also does not identify systemic ESG hazards such as data abuse, privacy violations, or environmental damage.

  From a Baillie Gifford perspective, this question asks whether society needs this company to exist. IDEXX's answer is highly positive: it is indispensable, with deep customer reliance and high replacement friction; its prosperity aligns with social benefit, as pets receive better diagnosis and treatment; and growth does not depend on harming others. This is exactly the kind of company Baillie Gifford would see as one society should allow to win over the long term, and it is IDEXX's least controversial positive point.

  Jun 11, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or deteriorate as scale grows? Where does the money it earns go?7/10

  A

  Conclusion: the unit economics are excellent: high gross margin, low capital expenditure, strong operating leverage, and they continue to improve as scale grows, with gross margin rising from 58% to 61.8% over 6 years. The money it earns mainly goes to internal reinvestment, small acquisitions, and buybacks. The only reservation is buybacks: they happen very frequently, but not always at cheap prices, so they look more like dilution offset and steady share-count reduction than founder-style countercyclical allocation that buys heavily only when undervalued. This is a typical high-quality compounding machine. The money is earned cleanly and spent rationally, though the odds discipline of capital allocation lacks some sharpness.

  Start with the absolute level of unit economics. In 2025, gross margin was 61.8%, operating margin 31.6%, and net margin 24.6%; capital expenditure was only $125 million, about 2.9% of revenue. This means each incremental dollar of revenue converts into operating profit and free cash flow at a very high rate, and growth barely needs large amounts of new capital to be purchased. 2025 free cash flow was $1.057 billion, about 100% of net income. The profit is cash profit, not paper profit.

  Now consider whether scale makes it better or worse. Clearly, it gets better. From 2020 to 2025, gross margin rose from about 58.0% to 61.8%, and operating margin also moved up overall, driven by economies of scale, with larger sample volume spreading laboratory fixed costs, pricing through net price realization, and product-mix improvement as high-value menus gain share. First-quarter gross margin also improved by about 90 basis points year over year. This is evidence of getting more profitable as it grows, not diseconomies of scale or declining marginal returns. Incremental returns, namely the later consumable/laboratory repeat revenue from new placements, remain rich. On that basis, the report estimates conservative 2025 Owner Earnings at about $1.05 billion, closely matching FCF.

  Where does the money it earns go? The report breaks it down clearly: mainly internal compounding, with small external additions:

  • Internal reinvestment. R&D for new menus and platforms such as inVue Dx and Cancer Dx, plus laboratory and software capabilities. This is the highest-return destination.
  • Small acquisitions. Disciplined: about $81.10 million for a software/data platform in 2024 and about $15.60 million for reference laboratory customer-relationship intangibles in 2025, both small, focused capability additions, with no wasteful large-scale M&A.
  • Buybacks. The company has long paid no dividend, and excess cash mainly goes to buybacks. In 2025, it repurchased about 2.411 million shares, spending $1.220 billion at an average price of about $506.07. From 2023 to 2025, diluted weighted-average shares fell from about 83.978 million to 81.025 million, steadily reducing share count and increasing per-share value density.

  Buybacks are the only area that deserves a discount. The report notes that in the first quarter of 2026, the company repurchased shares in February and March at average prices of about $644 and $594, respectively. Under this article's valuation framework, with reasonable intrinsic value at $300-$380, those prices are not cheap. In other words, buybacks look more like a mechanical action to keep retiring shares and offset SBC dilution than a countercyclical capital allocation decision to buy aggressively when undervalued. Equity compensation is small, with 2025 SBC of about $60.01 million, about 1.4% of revenue, but using expensive buybacks to neutralize SBC is economically not the same as zero cost.

  From a Baillie Gifford perspective, IDEXX scores full marks on unit economics and high but not full marks on capital allocation. The business's earning efficiency and incremental returns are beyond reproach, which is the foundation for its quality premium. The deduction is only that buybacks lack clear odds discipline. Put differently: how the money is earned is almost perfect; how the money is spent is rational but not sharp enough.

  Jun 11, 2026
• QWhat conditions must all hold for it to rise fivefold in 10 years? Are those conditions realistic? What expectations are embedded in today's share price?2/10

  A

  Conclusion: for IDEXX to rise fivefold in 10 years, about 17.5% per year, three things would have to happen at the same time: revenue growth would need to reaccelerate to double digits, margins would need to keep expanding, and a high valuation multiple would need to avoid material compression for 10 years. That directly conflicts with the company's current high-single-digit growth center and already elevated valuation starting point, so the realism is low. Worse, the current share price of about $557 already embeds optimistic expectations that the company will remain excellent for a long time, leaving almost no room for upside surprise and instead creating downside exposure if expectations are missed and the valuation is cut. This is the Baillie Gifford question where IDEXX most deserves cold water.

  First, break down what conditions must all hold for 5x in 10 years. A 5x return means a compound annual rate of about 17.5%. Equity returns can be roughly split into earnings-per-share growth multiplied by changes in the valuation multiple. To reach 17.5% per year, it needs at least:

  • Earnings compounding of about 13%-15% per year. This requires revenue to reaccelerate from the current high single digits, with 2026 guidance implying reported growth of about 8.6%-10.6%, back into double digits and sustain that for 10 years, plus continued margin expansion and share-count reduction through buybacks. But the report's base case puts Owner Earnings growth at 5%-8% per year, and even the optimistic case is only around 8%. Getting the earnings side to 13%-15% already requires continuous positive surprises.
  • The valuation multiple must not compress for 10 years. The current PE is about 41x, based on TTM EPS of $13.59, and P/FCF is about 42.5x. If a 5x outcome in 10 years relies on earnings growth of about 13%, or about 3.4x over 10 years, the valuation still needs to contribute about 1.5x, meaning the multiple would have to rise from 41x to about 60x. That would mean the market paying 50% more on top of an already expensive base, which conflicts with the common sense that a mature large company with slowing growth should see its multiple converge, not expand.

  Put these three together: reaccelerating revenue, further margin expansion, and an expanding or at least resilient multiple pull against each other directionally, because large companies with slowing growth usually see multiple contraction rather than expansion. So 5x in 10 years is not absolutely impossible, but it requires a chain of low-probability outcomes to occur at the same time. The realism is low. The report's optimistic scenario also gives only about 8%-11% annualized returns, or about 2-3x over 10 years, far short of 5x.

  Now consider what today's share price embeds. This is the heart of the question. At about $557 and roughly 78.90 million shares, equity market value is about $43.9 billion. Using conservative 2025 Owner Earnings of about $1.05 billion, the current price equals about 42x Owner Earnings, with a starting Owner Earnings yield of only about 2.4%. The report's three DCF scenarios produce intrinsic value ranges of about $240-$270 in the conservative case, $310-$360 in the neutral case, and $400-$460 in the optimistic case. The current price is about 55%-80% above the neutral range and still above the top end of the optimistic range.

  This means today's share price has already prepaid the entire optimistic narrative that IDEXX will maintain high-quality growth for a long time and that the market will always be willing to award it a high premium. In other words, buying at $557 is not buying a good company cheaply. It is paying a substantial entry fee for excellence that is already fully priced.

  The honest conclusion under the Baillie Gifford LTGG framework: Baillie Gifford is willing to pay high prices for true 5x-in-10-year candidates, but only when the upside imagination is large enough and the current price has not already extracted that imagination in advance. IDEXX's problem is exactly that it is a great company everyone can understand, its blue-sky elasticity is not large enough, with a high-single-digit steady state rather than exponential breakout, and the share price has already prepaid excellence quite fully. Buying today gives odds where successful execution may still produce only high-single-digit to low-double-digit returns, while a miss could trigger both valuation and fundamental downside. The report therefore rates it Watch and sets a reasonable buy range at $240-$320: wait for price and value to separate again, rather than chase expectations that are already embedded.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Is it because investors do not understand, dismiss it, or cannot look far enough? What will become the narrative inflection point?3/10

  A

  Conclusion: for IDEXX, this question must be answered in reverse. The market has not failed to realize how good it is. Quite the opposite: the market has long recognized it fully and has priced almost all of its excellence into the share price of about $557, with a PE of about 41x. This is not a case of investors not understanding or dismissing it; it is closer to understanding it too clearly and paying too fully. What is not fully priced is the risk on the other side: whether growth will continue slowing from high single digits, and whether chain bargaining power and AI will erode the premium. The so-called narrative inflection point is therefore not an upside discovery of good news, but a downside risk point around whether the high premium can be defended.

  First, correct the premise: this is not a stock that has been wrongly sold off or ignored. The most direct measure of whether the market has realized something is valuation. IDEXX's current PE is about 41x, with P/FCF of about 42.5x, while Zoetis, the animal health leader with the closest quality profile, currently trades at only about 13x PE, despite 2025 revenue of $9.467 billion and net income of $2.673 billion, both larger. The market's willingness to give IDEXX three times Zoetis's multiple shows that it has already recognized and paid for IDEXX's quality premium, compounding premium, and scarcity premium. So Baillie Gifford's question, why has the market not realized it yet, offers no cheap opportunity here. The excellence is visible, consensual, and already overdrawn.

  So among not understanding, dismissing, and not looking far enough, where does it land? None of the three really fits. If forced, it is a combination of paying too fully and some inability to look far enough on the risk side:

  • It is not a failure to understand. This razor-holder-and-razor-blade business is easy to understand. The report gives business understandability 4.5/5; CAG Diagnostics recurring revenue accounts for about 79.2% of total revenue, repeat usage is clearly visible, and institutional coverage is ample.
  • It is not dismissal. A 41x PE is itself proof of extreme respect. The market is paying a premium, not applying a discount.
  • What the market may not look far enough on is the risk side. It may underestimate the possibility of a lower growth step and multiple convergence: the report notes that industry visit volumes slowed in 2024 and the company cut guidance several times, while chain bargaining power, including Mars/NVA and buying consortiums, and AI disruption of interpretation are slow-moving variables. If these variables materialize, today's 41x pricing has little margin for error.

  What will the narrative inflection point be? Since the upside room from discovering excellence has already been extracted, the inflection point is more likely to come when the excellence narrative is disproven or weakens. The trigger list in the report describes exactly these downside inflection forms: CAG Diagnostics recurring revenue growth falling to mid-to-low single digits for several consecutive quarters with no clear recovery path; premium installed-base growth slowing materially or turning negative; meaningful loss of large chain customers or switching to competitors; sustained decline in gross margin/operating margin without a major strategic investment explanation; long-term divergence between free cash flow and net income, abnormal swelling of contract assets; or interruption at a key single-source supplier, Ortho for Catalyst chemistry slides. If any of these is confirmed, the market may reclassify IDEXX from a high-certainty compounding platform into a high-quality medical equipment/service provider with slowing growth, with the multiple converging from the 40x range toward 30x or even lower.

  There is also an upside inflection point, but the bar is high: if inVue Dx, Cancer Dx, and other in-clinic AI diagnostics scale significantly and lift overall growth back to double digits, the market may continue to award a full premium. The report's judgment, however, is that these engines are more likely to extend the runway than shift gears, so the probability of upside re-rating is lower than the probability of downside convergence.

  The honest Baillie Gifford summary: the standard answer to this question, that the market does not understand a good company, fails for IDEXX. This is a company whose excellence is already consensus and fully priced. The perception gap is not in an undiscovered good thing, but in whether the already-priced good thing can hold. For long-term investors, the key is therefore not waiting for the market to wake up, but waiting for the market to offer a better price. The report's Watch rating and reasonable buy range of $240-$320 exist because at $557, the downside risk from narrative inflection is clearly greater than upside re-rating room.

  Jun 11, 2026